Key result
Exogenous Threonyl-tRNA synthetase (TARS) stimulates endothelial cell migration and angiogenesis, which is inhibited by the borrelidin derivative BC194.
Why the study?
Does exogenous TARS stimulate angiogenesis and endothelial cell migration in preclinical models?
Does exogenous TARS stimulate angiogenesis and endothelial cell migration in preclinical models?
TARS acts as an extracellular signaling molecule that promotes angiogenesis and endothelial cell migration, providing a potential target for inflammatory or angiogenic diseases.
TARS may serve as an extracellular angiogenic signal in preclinical models; leaves open translation to human inflammatory or angiogenic diseases.
Aminoacyl-tRNA synthetases classically regulate protein synthesis but some also engage in alternative signaling functions related to immune responses and angiogenesis. Threonyl-tRNA synthetase (TARS) is an autoantigen in the autoimmune disorder myositis, and borrelidin, a potent inhibitor of TARS, inhibits angiogenesis. We explored a mechanistic link between these findings by testing whether TARS directly affects angiogenesis through inflammatory mediators. When human vascular endothelial cells were exposed to tumor necrosis factor-α (TNF-α) or vascular endothelial growth factor (VEGF), TARS was secreted into the cell media. Furthermore, exogenous TARS stimulated endothelial cell migration and angiogenesis in both in vitro and in vivo assays. The borrelidin derivative BC194 reduced the angiogenic effect of both VEGF and TARS, but not a borrelidin-resistant TARS mutant. Our findings reveal a previously undiscovered function for TARS as an angiogenic, pro-migratory extracellular signaling molecule. TARS thus provides a potential target for detecting or interdicting disease-related inflammatory or angiogenic responses.
No takes yet. Share an insight, caveat, or question.
Williams et al. (2013) studied Angiogenesis. Threonyl-tRNA synthetase (TARS) vs. Control (PBS or low serum) was evaluated on Endothelial cell tube formation and CAM vascularity. Exogenous Threonyl-tRNA synthetase (TARS) stimulates endothelial cell migration and angiogenesis, which is inhibited by the borrelidin derivative BC194.